No Data
No Data
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
Satellos Announces Participation in September 2024 Investor Conferences
Satellos Bioscience Brief: Announcing Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial With SAT-3247
Satellos Bioscience Says Latest Canine Data Involving SAT-3247 Is Promising, Q2 Loss Widens
Satellos Bioscience Brief: Adds "On Track: to Dose First Participant in Phase 1 Clinical Trial With SAT-3247 in Q3 2024; Cites Cash Balance of $27.7 Million at June 30, 2024
Satellos Bioscience Brief: Cites Receipt of Orphan Drug and Rare Pediatric Disease Designations From US FDA
No Data